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Abstract
Objective
To assess resting cerebral blood ﬂow (CBF) in the whole-brain and cerebral white matter
(WM) and gray matter (GM) of adults with Fabry disease (FD), using arterial spin labeling
(ASL)MRI, and to investigate CBF correlations with WM hyperintensity (WMH) volume and
the circulating biomarker lyso-Gb3.
Methods
This cross-sectional, case-control study included 25 patients with genetically conﬁrmed FD and
18 age-matched healthy controls. We quantiﬁed resting CBF using Quantitative Signal
Targeting With Alternating Radiofrequency Labeling of Arterial Regions (QUASAR) ASL
MRI. We measured WMH volume using semiautomated software. We measured CBF in
regions of interest in whole-brain, WM, and deep GM, and assessed correlations with WMH
volume and plasma lyso-Gb3.
Results
The mean age (% male) for FD and healthy controls was 42.2 years (44%) and 37.1 years (50%).
Mean whole-brain CBF was 27.56 mL/100 mL/min (95% conﬁdence interval [CI] 23.78–31.34)
for FD vs 22.39 mL/100 mL/min (95% CI 20.08–24.70) for healthy controls, p = 0.03. In WM,
CBF was higher in FD (22.42 mL/100 mL/min [95% CI 17.72–27.12] vs 16.25 mL/100 mL/min
[95% CI 14.03–18.48], p = 0.05). In deep GM, CBF was similar between groups (40.41 mL/100
mL/min [95% CI 36.85–43.97] for FD vs 37.46 mL/100 mL/min [95% CI 32.57–42.35], p =
0.38). In patients with FD with WMH (n = 20), whole-brain CBF correlated with WMH volume
(r = 0.59, p = 0.006), not with plasma lyso-Gb3.
Conclusion
In FD, resting CBF is increased in WM but not deep GM. In FD, CBF correlates with WMH,
suggesting that cerebral perfusion changes might contribute to, or result from, WM injury.
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Fabry disease (FD) is an X-linked disease due to deﬁciency of
lysosomal α-galactosidase A, causing widespread cellular
accumulation of glycosphingolipids, including globo-
triaosylceramide (Gb3).1 Clinical features include cutaneous
capillary lesions (angiokeratomata), painful peripheral neu-
ropathy (acroparesthesia), hypertrophic cardiomyopathy,
chronic renal impairment, and cerebrovascular disease. Blood
vessel (including endothelial) dysfunction, due to prominent
vascular lipid deposition, is likely to contribute to clinical
CNS features of FD. Indeed, ischemic stroke occurs in up to
20% of patients with FD,2,3 while cognitive and mood
impairments are also common.4,5 Characteristic MRI features
of FD include white matter (WM) hyperintensities (WMH),6
lacunar infarcts,7 and microbleeds,8,9 suggesting that small
vessel disease (SVD) contributes to its cerebrovascular
consequences.
FD vasculopathy might relate to cerebrovascular disease by
altering cerebral blood ﬂow (CBF), which is quantiﬁable as
a potential biomarker to detect and monitor the disease.
Previous studies on CBF in FD, mainly using PET in hemi-
zygous males,10–12 have been conﬂicting.13 Arterial spin
labeling (ASL) MRI allows noninvasive measurement of CBF
without ionizing radiation.14 We used Quantitative Signal
Targeting With Alternating Radiofrequency Labeling of
Arterial Regions (QUASAR) ASL MRI, a reproducible and
accurate technique,15 to test the following hypotheses: (1)
CBF is altered in male and female patients with genetically
conﬁrmed FD, compared to matched healthy controls; (2)
CBF is altered to diﬀerent extents in WM and deep gray
matter (GM); and (3) in the whole group, CBF is correlated
with WMH volume (a marker of SVD), and, in the FD group,
with circulating lyso-Gb3 (a putative biomarker of disease
severity).
Methods
Study population
Inclusion criteria were genetically conﬁrmed FD referred to
the National Hospital for Neurology and Neurosurgery,
above the age of 18, and with no contraindication to MRI
scanning. Healthy adult volunteers, matched as closely as
possible for age and sex (as a group), were also recruited for
comparison. Patients with other known CNS diseases were
excluded. Eligible participants were recruited consecutively
from April 2012 to July 2013; each participant underwent
detailed clinical assessment, blood testing, and MRI brain
scanning during a single visit.
Standard protocol approvals and
patient consents
The Joint Research Ethics Committee of the UCL Institute of
Neurology and National Hospital for Neurology and
Neurosurgery, London, UK, approved the study. We obtained
written informed consent from each participant.
MRI acquisition and postprocessing
We used a 3.0T MRI scanner with a 32-channel receive coil
(Phillips Healthcare Systems, Best, the Netherlands). The
center axial section was orientated along the subcallosal line.
We assessed CBF using the QUASAR sequence: a multiple
time point, pulsed ASL sequence. The scan parameters were
repetition time (TR) 4,000 ms, echo time (TE) 23 ms,
13 inversion times (40–3,640 ms), DT1 300 ms, ﬁeld of view
240 × 240, voxel size 3.75 × 3.75 × 6 mm3, 7 axial slices, slice
gap 2 mm, ﬂip angle = 35/11.7°, sensitivity encoding = 2.5, 84
averages (48 with vascular crusher gradients of 4 cm/s,
24 with no vascular crusher gradients, 12 with low ﬂip angle),
scan time 6 minutes 7 seconds.
We performed postprocessing using a Windows 7 PC
(Microsoft, Redmond, WA) running IDL 6.1 (ITT Visual
Information Solutions, Boulder, CO), which produced maps
of CBF and tissue R1 (1/T1; longitudinal relaxation rate). To
help with the placement of regions of interest (ROI), we
acquired a fast spin echo multiecho scan with the following
measures: TR 5,230 ms, TE1 16 ms, ΔTE 16 ms, 7 echoes,
ﬁeld of view 240 × 180 × 152 mm3, voxel size 1 × 1 × 2 mm3,
90 axial slices, acquisition time 6 minutes 48 seconds. The
fourth echo, corresponding to a TE of 64 ms, was also used for
lesion identiﬁcation as a T2-weighted scan. We acquired
a T1-weighted 3D turbo gradient echo sequence with the
following measures: TR 6.9 ms, TE 3.1 ms, inversion time 824
ms, ﬁeld of view 256 × 256 × 180, voxel size 1 × 1 × 1 mm3,
180 sagittal slices, scan time 6 minutes 31 seconds.
ROI identification
We registered proton density (PD) T2-weighted images to the
R1 map calculated from theQUASAR sequence using an aﬃne
transformation with the NiftyReg toolkit (University College
London; sourceforge.net/projects/niftyreg). We placed ROIs,
each 6 × 6 voxels, onto the R1 map using the registered PD T2
images as a guide by a single trained radiology trainee (P.P.).
An experienced vascular neuroradiology consultant (I.D.)
veriﬁed all ROI placements. A total of 23 ROIs were placed in
both right and left cerebral hemispheres, using Jim 6.0
(Xinapse systems [xinapse.com]): 15 in WM and 8 in deep
Glossary
ASL = arterial spin labeling; CBF = cerebral blood ﬂow; CI = conﬁdence interval; ERT = enzyme replacement therapy; FD =
Fabry disease; Gb3 = globotriaosylceramide; GM = gray matter; PD = proton density; QUASAR = Quantitative Signal
Targeting With Alternating Radiofrequency Labeling of Arterial Regions; ROI = region of interest; SVD = small vessel disease;
TE = echo time; TR = repetition time; WM = white matter; WMH = white matter hyperintensities.
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GM.TheWM regions were frontal lobe (above the ventricles),
frontal lobe (at the level of the ventricles), frontal lobe (below
the ventricles), parietal lobe, occipital lobe, temporal lobe
anterior pole, genu of the corpus callosum, splenium of the
corpus callosum, and central pons. The GM regions were
anterior thalamus, thalamic pulvinar, caudate head, and puta-
men. Examples of the ROI placements are shown in ﬁgure 1.
Clinical measures
Participants were all assessed on the same day as their MRI.
We recorded demographic data using a standardized case
report form.
Whole-brain WM lesion quantification
WM lesions were assessed for volume on the PD T2 scans as
bright lesions >2 mm, using the phase-sensitive inversion
recovery images for anatomical referencing. Hyperintense
lesions (>2 mm) around the anterior commissure (anterior
perforating substance) were again excluded as larger peri-
vascular spaces are commonly found in this area. By this
deﬁnition, WM lesions on all participant MRI examinations
were segmented using JIM version 5.0 (Xinapse Systems,
Northants). A semiautomated method for ROI placement
was used: ROIs were automatically assigned over lesions and
reﬁned manually by consensus between a trained observer
and experienced vascular neuroradiology consultant. The
mean total ROI volume was calculated automatically.
Plasma globotriaosylsphingosine (lyso-Gb3) was measured
using a rapid multiplexed assay developed at UCL Institute of
Child Health (Dr. Kevin Mills) with a reference range 0–1.8
ng/mL.
Statistical analysis
We performed all analyses in Stata 12.1 (Stata Corporation,
College Station, TX). Since our values were not normally
distributed and unpaired, we used nonparametric statistical
tests. We calculated mean CBF of whole-brain by obtaining
the mean of all available ROI for each patient. We compared
whole-brain mean CBF between patients and controls using
the nonparametric rank sum test. Mean WM and deep GM
mean CBF was also calculated for each patient from all
available ROIs, and then compared between the patients and
controls using nonparametric rank-sum test. Median CBF
and interquartile range was calculated for CBF from the
diﬀerent regions of the brain. Results were presented as
means with 95% conﬁdence intervals (CIs); statistical sig-
niﬁcance was taken to be p ≤ 0.05. Spearman rho correlation
coeﬃcients were calculated for measuring the relationship
between CBF and clinical measures in FD, including WMH
volume and lyso Gb-3. We excluded patients with FD with
zero WMH from correlation analyses.
Results
General demographics
Twenty-ﬁve patients and 18 healthy controls were included in
the study. The details of study participants are shown in
table 1.
Figure 1 Representative regions of interest, identified on the R1 images
Regions of interest are shown as red
boxes. (A) Anterior temporal lobe
and central pons. (B) Occipital lobes.
(C) Frontal lobes below the level of
the ventricles. (D) Corpus callosum
genu and splenium, putamen, ante-
rior thalamus, and thalamic pulvinar.
(E) Frontal lobes above the ventricles.
(F) Frontal lobes above the ventricles,
and parietal lobes.
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Cerebral blood flow
The mean whole-brain CBF (derived from the mean of all
available ROI from each patient) was 27.56 mL/100 mL/min
(95% CI 23.78–31.34) for FD vs 22.39 mL/100 mL/min
(95%CI 20.08–24.70) for healthy controls; p = 0.03 (table 2).
In WM regions, CBF was higher in FD (22.42 mL/100 mL/
min [95% CI 17.72–27.12] vs 16.25 mL/100 mL/min [95%
CI 14.03–18.48]) (p = 0.05). By contrast, in deep GM there
was no diﬀerence in CBF between groups (40.41 mL/
100 mL/min [95% CI 36.85–43.97] for FD vs 37.46 mL/
100mL/min [95%CI 32.57–42.35] for healthy controls) (p =
0.38] (table 2). CBF was increased in all individual ROIs in
the FD group compared to the healthy control group, except
for the parietal lobe and thalamic pulvinar (table 2), though
the diﬀerence was only statistically signiﬁcant for the corpus
callosum splenium. Representative CBF maps from a healthy
control and a participant with Fabry disease are shown in
ﬁgure 2. The clinical characteristics and proﬁle of patients by
sex are detailed in table 3 and table e-1 (links.lww.com/WNL/
A361). No diﬀerence was seen between enzyme replacement
therapy (ERT) treated and nontreated patients with FD for
measure of whole-brain CBF, GM CBF, WM CBF, or
lysoGb3 on univariate analysis (table e-2).
Correlation of CBF with WM hyperintensities
and biomarkers
The mean volume of WMH in patients with FD was
1,972.6 mm3, compared to 203.1 mm3 in healthy controls (p =
0.004). In the normal control group, 11 of 18 (61%) had no
WMH, while in the FD group, only 5 of 25 (20%) had no
WMH. In patients with FD with WMH (n = 20), whole-brain
CBF correlated with WMH volume (r = 0.59, p = 0.006). In
Table 1 Characteristics of participants
Fabry disease
(n = 25)
Healthy
controls
(n = 18)
Male, n (%) 11 (44) 9 (50)
Age, y, mean (range) 42.2 (26–70) 37.1 (27–65)
Right-handedness, n (%) 23 (92) 17 (94)
Hypertension, n (%) 8 (32) 1 (6)
History of ischemic stroke, n (%) 2 (8) 0
History of intracerebral
hemorrhage, n (%)
1 (4) 0
White matter hyperintensity
total volume, mm3, mean (SD)
1,972.6 (5,543.0) 203.1 (481.8)
Abbreviation: CI = confidence interval.
Table 2 Comparison of mean cerebral blood flow (CBF) in whole-brain, white matter, and deep matter for participants
with Fabry disease and healthy controls
Fabry disease (n = 25) Healthy controls (n = 18) p Valuea
Mean CBF (whole-brain, including gray and white matter),
mL/100, mL/min (95% CI)
27.56 (23.78–31.34) 22.39 (20.08–24.70) 0.03
Mean CBF (white matter), mL/100, mL/min (95% CI) 22.42 (17.72–27.12) 16.25 (14.03–18.48) 0.05
Mean CBF (deep gray matter), mL/100, mL/min (95% CI) 40.41 (36.85–43.97) 37.46 (32.57–42.35) 0.38
White matter regions, mean CBF, mL/100, mL/min (95% CI)
Frontal 15 (10.9–17.3) 11.4 (10.7–18.4) 0.4
Parietal 13.1 (9.7–16.9) 14.1 (10.5–17.4) 0.6
Occipital 11.5 (7.8–16.3) 9.5 (8.5–12.7) 0.4
Temporal 24.1 (11.8–53.4) 23.1 (11.7–27.0) 0.4
Corpus callosum genu 15.2 (10.2–20.6) 13.2 (7.1–23.3) 0.4
Corpus callosum splenium 22.8 (16.9–38.4) 12.7 (8.5–16.6) 0.0008
Central pons 29.2 (20.2–40.2) 26.2 (19.5–37.5) 0.8
Deep gray matter regions, mean CBF, mL/100, mL/min (95% CI)
Anterior thalamus 44.4 (33.8–48.3) 40.2 (31.3–49.3) 0.7
Pulvinar 39.9 (28.8–52.5) 41.0 (30.0–54.4) 0.6
Putamen 34.4 (31.1–46.4) 33.5 (23.5–40.5) 0.09
Caudate head 42.4 (35.5–47.8) 33.6 (30.1–46.4) 0.08
Abbreviation: CI = confidence interval.
a Wilcoxon rank-sum test.
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patients with FD, lyso-Gb3 levels did not correlate with CBF
in the whole-brain (Spearman rho = −0.023, p = 0.9), in WM
(Spearman rho = 0.02, p = 0.94), or in deep GM (Spearman
rho = 0.005, p = 0.8). There was no correlation between lyso-
Gb3 levels and total volume of WMH (Spearman rho = 0.1,
p = 0.6).
Discussion
In our sample of 25 patients with FD (including both male
and female patients), we found increased whole-brain CBF in
comparison to 18 age-matched healthy controls. The mean of
CBF measurements from WM regions was statistically
signiﬁcantly higher than in the mean value from deep GM
regions, although the only individual WM region with
increased CBF in patients with FD was the splenium of the
corpus callosum. In patients with FD with WMH (n = 20),
whole-brain CBF correlated with WMH volume (r = 0.59,
p = 0.006), but none of the CBF measures (in whole-brain,
WM, or deep GM) correlated with plasma lyso-Gb3.
Our CBF measures were broadly comparable to previously
published data using a similar technique, suggesting that our
data are reliable. A previous QUASAR studymeasured CBF in
13 healthy patients, with average CBF 38 mL/100 mL/min
for GM and 23 mL/100 mL/min for WM.16 The GM value
was almost equal to that observed in our healthy controls, but
in our healthy control cohort WM CBF was slightly lower
(16.46 mL/100 mL/min); however, our healthy controls
(mean 37.1 years) are older than those in the previous study,
and the method of quantifying CBF was diﬀerent, based on
Figure 2 Representative cerebral blood flow (CBF) maps from a healthy control (top row) and a participant with Fabry
disease (bottom row)
CBF is shown on a hotwire scale between
0 and 100 mL/min/100 g. Note that CBF is
clearly increased in the participant with
Fabry disease (bottom row).
Table 3 Clinical featuresof thepatientswith Fabrydisease
Clinical features Values
Angiokeratomas, n (%) 11 (44)
Hearing impairment, n (%) 6 (24)
Anhidrosis/hypohidrosis, n (%) 5 (20)
Microalbuminuria (30–300 mg/24 h), n (%) 5 (20)
eGFR <60 mL/min/1.73 m2, n (%) 1 (4)
LVM index >50 g/m2, n (%) 4 (16)
ERT, n (%) 18 (72)
Fabry International Prognostic Index, median (IQR) 1 (0–2)
Fabry International Prognostic Index
neurologic subscore, median (IQR)
0 (0–2.5)
Abbreviations: eGFR = estimated glomerular filtration rate; ERT = enzyme
replacement therapy; IQR = interquartile range; LVM = left ventricular mass.
GLA gene mutations identified: c. 274 G>C (p.Asp92his) (n = 2); c.319C>T
(p.Gln107X); c.335 g>A (p.Arg112his); c.352C>T (p.Arg118Cys); c.613C>A
(p.Pro205thr) (n = 3); c. 644A>G (p.Asn215ser) (n = 2); c.679C>T (p.Arg227X);
c.772 G>T (p.Gly258trp); c.859T>G (p.Trp287gly); c.902 G>A (p.Arg301gln) (n =
2); c. 950T>Cp.Ile317Thr; c.1067G>Ap.Arg356Gln; c.1087C>Tp.Arg363Cys (n=
2); c.1229C>T (p.Thr410Ile); c.1033_1034delTC (p.Ser345Rfs*28) (n = 2);
c.1223delA (p.Asn408lfs*9); c. 547 +1 G>C g.IVS3+1 G>C n = 2; c716 INST
(p.1239 fs*10). The Fabry International Prognostic Index was calculated as
described in reference 28.
Neurology.org/N Neurology | Volume 90, Number 16 | April 17, 2018 e1383
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
a mean derived from ROIs rather than from calculated CBF
measures through all acquired slices.
Our results are in keeping with previous reports using PET
studies suggesting increased CBF in FD11,12,17,18; however,
these earlier studies were limited to male patients, while we
included a representative cohort of both male and female FD
patients with FD. Moreover, the previous studies have not
fully established the pattern of perfusion changes in WM and
GM in FD.
Our ﬁndings not only conﬁrm that FD is associated with
increased CBF, but also suggest that the WM is particularly
vulnerable to hemodynamic alterations. The correlation be-
tween CBF and WMH in FD suggests that increased CBF
might be relevant to the pathogenesis of WM injury,
which—from the high prevalence in MRI studies (typically
around 40%)19—might be central to the cerebrovascular
complications in both male and female patients, though we
are not aware of evidence linking WMH to future stroke risk
in FD. Although, intuitively, sphingolipid deposition in cere-
bral vessels in FD disease might be expected to reduce CBF,
several mechanisms could contribute to elevated CBF in FD.
Chronic nitric oxide pathway dysregulation in FD11 can
generate peroxynitrite, which induces cerebral vasodilation
and resists vasoconstriction by humoral mediators, increasing
CBF.11 Alternatively, the sphingolipid pathway abnormality in
FD could lead to abnormal excess compensatory neuronal
activity, increased neuronal–blood ﬂow coupling, and cerebral
hyperperfusion, as is seen in other lysosomal storage disease
such as Salla disease, a defect of sialic acid metabolism.20 One
possibility is that metabolic insuﬃciency resulting from neu-
ronal dysfunction in FD could cause a compensatory increase
in CBF, which may be an adaptive or protective eﬀect to
reduce chronic cerebral hypoxic injury.4 Although the
mechanisms of possible hyperperfusion in FD remain unclear,
raised CBF may injure vascular walls of WM perforating
arteries by shear stress,21 which can stimulate endothelial cells
to translate the mechanical stimulus into biochemical signals,
causing vascular remodeling by upregulation of growth factors
or components of the vessel wall21; this could in turn lead to
WMH or ischemic stroke through an occlusive vasculopathy.5
Increased CBF could also increase capillary leakage and
macromolecular content of the extracellular space, causing
parenchymal cerebral damage and potentially functional im-
pairment of cognition.8
Our ﬁndings may also have relevance for FD pathogenesis
since the WMH in age-related sporadic cerebral small vessel
disease may be indistinguishable (on structural MRI) from
those seen in FD, causing diagnostic challenges, especially in
older individuals with vascular risk factors. Perfusion studies
in sporadic SVD have shown reduced CBF in both normal-
appearing and abnormal WM,22,23 suggesting that WMH re-
sult from reduced perfusion along penetrating arterioles
causing ischaemic injury in deep WM regions with lowest
perfusion pressure. Our data thus suggest a fundamental
diﬀerence in mechanism underlying WMH in FD compared
to sporadic SVD, which may make MRI perfusion a useful
noninvasive method to distinguish between these 2 processes.
We found increased CBF in all brain regions except for the
parietal lobe WM and thalamic pulvinar. By contrast with our
ﬁndings, a previous small study of MRI perfusion using
arterial spin tagging in 3 patients reported increased blood
ﬂow in the pulvinar in FD24 associated with the pulvinar sign
of T1 hyperintensity. We systematically measured thalamic
pulvinar CBF in a larger cohort and found no diﬀerence;
moreover, none of our patients showed the T1 hyperintense
pulvinar sign, which in the previous study was suggested to be
pathognomonic of FD.24 More recent studies suggest that,
although characteristic of FD, the pulvinar sign is only present
in 25% of male patients, and is absent in female patients with
FD.25 Our ﬁndings of apparently greater WM involvement is
diﬀerent from those of a previous study using PET, which
found the abnormality in resting CBF in FD to be equally
distributed between WM and GM,11 suggesting a global
disease process rather than a selective vulnerability. However,
the previous study included only male patients, and used
a diﬀerent method of measuring CBF. Furthermore, another
study by the same group found hyperperfusion in WM of
patients with FD, as well as reduced metabolism in theWM.26
The authors speculate that increased perfusion is a key
mechanism underlying WM injury in FD, a hypothesis
supported by our ﬁndings.
Our study has strengths. Patients were prospectively recruited
and studied using a standardized MRI and clinical protocol. A
single trained observer undertook all of the MRI analysis, and
an expert neuroradiologist veriﬁed all ROI placements. Our
sample size is large for a disease as rare as FD, though it is still
possible that we were unable to show statistically signiﬁcant
changes in some brain regions (e.g., deep GM) because of
limited participant numbers. We also included both male and
female patients, unlike previous studies conﬁned to male
participants. Some limitations of our data should also be
noted, including the exclusion of patients with MRI contra-
indications, for example those with severe cardiac in-
volvement and implantable cardiac devices. Our ﬁndings may
therefore not be generalizable to the full spectrum of patients
with FD. Our study was cross-sectional and cannot establish
the causal relationship between CBF andWMH. Moreover, it
is possible that ERT had diﬀerential eﬀects on CBF and on
lyso-Gb3; ideally a cohort of untreated patients is required to
study the relationship between CBF and plasma lyso-Gb3.We
have not investigated howCBF is linked to cognitive function,
which merits further study.
CBF is increased in FD, with a predilection for WM rather
than GM regions. Furthermore, CBF is modestly correlated
with WMH volume, suggesting a pathophysiologic link
among blood ﬂow changes, SVD, and WM injury. The lack of
correlation with lyso-Gb3 suggests that CBF might provide
useful information about FD progression, not directly related
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to circulating levels of the abnormally accumulated sphingo-
lipid. However, our study was not able to investigate the
relationship between CBF changes to longer term clinically
meaningful outcome for patients (or the eﬀects of ERT).
Since MRI ASL sequence is noninvasive, free from ionizing
radiation, and reproducible at diﬀerent centers, CBFmay be an
attractive biomarker in FD with relevance for diagnosis, and for
detecting and monitoring cerebrovascular involvement. Other
noninvasive methods might also have potential in FD; for ex-
ample, cortical vascular dysfunction in the territory of the
posterior circulation has also been described in a transcranial
Doppler study in adult patients with FD.27 Furthermore, as
CBF changes may potentially be reversible,11 CBF measured
using an ASL technique may be an eﬃcient surrogate marker
for studies of new treatment strategies in FD.
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Study question
Do adults with Fabry disease (FD) have diﬀerences in re-
gional cerebral blood ﬂow (CBF) relative to healthy controls?
Summary answer
Adults with FD have elevated CBF in the white matter but not
in the deep gray matter.
What is known and what this paper adds
FD is associated with large and small vessel vasculopathies,
but past studies into whether patients have elevated CBF have
reported conﬂicting results. This study reports arterial spin
labeling (ASL) MRI results that support the hypothesis of
elevated CBF in FD.
Participants and setting
This study consecutively recruited 25 adults with genetically
conﬁrmed FD (11 men; mean age, 42.2 years; range, 26–70
years) who were referred to the UK National Hospital for
Neurology and Neurosurgery between April 2012 and July
2013. This study also recruited 18 age- and sex-matched healthy
controls (9 men; mean age, 37.1 years; range, 27–65 years).
Design, size, and duration
For CBF quantiﬁcation, the participants underwent quanti-
tative arterial spin labeling MRI. CBF was assessed within 23
regions of interest, including 15 in the white matter and 8 in
the deep gray matter.
Primary outcomes
The primary outcome was CBF within the whole brain, white
matter, and deep gray matter.
Main results and the role of chance
The mean whole-brain CBF was greater in patients with FD
than in healthy controls (27.56 mL/100mL/min vs 22.39 mL/
100 mL/min; p = 0.03). The same was true for mean CBF in
the white matter (22.42 mL/100 mL/min vs 16.25 mL/
100mL/min; p = 0.05) but not for mean CBF in the deep gray
matter (40.41 mL/100 mL/min vs 37.46 mL/100 mL/min;
p = 0.38).
Bias, confounding, and other reasons
for caution
This study could not investigate the relationship between
CBF levels and long-term clinically meaningful outcomes.
Generalizability to other populations
This study excluded patients with contraindications to MRI,
such as severe cardiac involvement or implantable cardiac
devices. This may limit the generalizability of the results.
Study funding/potential competing interests
This research was funded by Shire Pharmaceuticals. The
authors report no competing interests besides that funding.
Go to Neurology.org/N for full disclosures.
Figure Representative CBF maps from a healthy control
and a patient with FD
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